AbstractChronic myeloid leukemia (CML) is a clonal malignancy initiated by the occurrence of a t (9;22) translocation, generating Ph1 chromosome and BCR-ABL oncogene in a primitive hematopoietic stem cell (HSC). The resistance of HSC to targeted therapies using tyrosine kinase inhibitors remains a major obstacle towards the cure. We have generated an iPSC line from a patient with CML using leukemic CD34+ cells cryopreserved at diagnosis. Ph1+ CML cells were reprogrammed by non-integrative viral transduction. These iPSCs harboured Ph1 chromosome and expressed pluripotency hallmarks as well as BCR-ABL. Teratoma assays revealed normal differentiation after injection in immunodeficient mice
Chronic myeloid leukemia (CML) is an excellent model of the multistep processes in cancer. Initiatin...
Chronic myeloid leukemia (CML) is a clonal stem cell disorder that is characterized by the acquired ...
La leucémie myéloïde chronique (LMC) est un syndrome myéloprolifératif clonal initié par l’activité ...
AbstractChronic myeloid leukemia (CML) is a clonal malignancy initiated by the occurrence of a t (9;...
Chronic myeloid leukemia (CML) is a clonal malignancy initiated by the occurrence of a t (9;22) tran...
AbstractA definitive cure for chronic myeloid leukemia (CML) requires identifying novel therapeutic ...
Abstract CML is a myeloproliferative disorder characterized by unregulated growth of ...
Chronic myeloid leukemia disease (CML) found effective therapy by treating patients with tyrosine ki...
CML (chronic myeloid leukaemia) is a myeloproliferative disease that originates in an HSC (haemopoie...
Chronic myeloid leukemia (CML) is caused by the BCR-ABL fusion protein, which dysregulates tyrosine ...
Induced pluripotent stem cells (iPSCs) can be generated from various differenti-ated cell types by t...
BCR-ABL tyrosine kinase inhibitors (TKIs) are effective in controlling Philadelphia-positive (Ph+) c...
がん進展制御研究所Although discovery of the tyrosine kinase inhibitor (TKI) imatinib mesylate has significant...
Chronic myeloid leukemia (CML) is typified by robust marrow and extramedullary myeloid cell producti...
Chronic myeloid leukemia (CML) is a clonal myeloproliferative malignancy initiated by tyrosine kinas...
Chronic myeloid leukemia (CML) is an excellent model of the multistep processes in cancer. Initiatin...
Chronic myeloid leukemia (CML) is a clonal stem cell disorder that is characterized by the acquired ...
La leucémie myéloïde chronique (LMC) est un syndrome myéloprolifératif clonal initié par l’activité ...
AbstractChronic myeloid leukemia (CML) is a clonal malignancy initiated by the occurrence of a t (9;...
Chronic myeloid leukemia (CML) is a clonal malignancy initiated by the occurrence of a t (9;22) tran...
AbstractA definitive cure for chronic myeloid leukemia (CML) requires identifying novel therapeutic ...
Abstract CML is a myeloproliferative disorder characterized by unregulated growth of ...
Chronic myeloid leukemia disease (CML) found effective therapy by treating patients with tyrosine ki...
CML (chronic myeloid leukaemia) is a myeloproliferative disease that originates in an HSC (haemopoie...
Chronic myeloid leukemia (CML) is caused by the BCR-ABL fusion protein, which dysregulates tyrosine ...
Induced pluripotent stem cells (iPSCs) can be generated from various differenti-ated cell types by t...
BCR-ABL tyrosine kinase inhibitors (TKIs) are effective in controlling Philadelphia-positive (Ph+) c...
がん進展制御研究所Although discovery of the tyrosine kinase inhibitor (TKI) imatinib mesylate has significant...
Chronic myeloid leukemia (CML) is typified by robust marrow and extramedullary myeloid cell producti...
Chronic myeloid leukemia (CML) is a clonal myeloproliferative malignancy initiated by tyrosine kinas...
Chronic myeloid leukemia (CML) is an excellent model of the multistep processes in cancer. Initiatin...
Chronic myeloid leukemia (CML) is a clonal stem cell disorder that is characterized by the acquired ...
La leucémie myéloïde chronique (LMC) est un syndrome myéloprolifératif clonal initié par l’activité ...